DYN
Dyne Therapeutics, Inc.- Healthcare
- Biotechnology
- $2.92B market cap
Forecast run · Oct 29, 2026Upside rank 1171 of 3,186
Model Signal
ForecastQ Daily Probabilities
31.8%
68.0%
24.6%
Analyst Consensus
Recommendation2.14/5 Buy
Last price$15.62
Price target$35.20
Implied move+125.4%
Analysts14
ForecastQ Portfolios
Company Profile
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.